Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 30000
Summary
- Conditions
- COVID-19
- Sars Cov 2
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants are assigned to one of two or more groups in parallel for the duration of the study.Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double Blind: two or more parties are unaware of the intervention assignment.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Both males and females
Description
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would ha...
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
Tracking Information
- NCT #
- NCT04516746
- Collaborators
- Iqvia Pty Ltd
- Investigators
- Principal Investigator: Ann Falsey, MD University of Rochester Principal Investigator: Magda Sobieszczyk, MD Columbia University
Get Well Soon